Distinct Regulation of NNOS and INOS by CB2 Receptor in Remote Delayed Neurodegeneration

Overview

Journal J Mol Med (Berl)

Specialty General Medicine

Date 2011 Dec 27

PMID 22198001

Citations 23

Authors

S Oddi

L Latini

M T Viscomi

E Bisicchia

M Molinari

M Maccarrone

Affiliations

Soon will be listed here.

Abstract

Hemicerebellectomy results in remote delayed degeneration of precerebellar neurons. We have reported that such a lesion induces type 2 cannabinoid receptor (CB(2)) expression in precerebellar neurons and that stimulation of CB(2), but not CB(1), has neuroprotective effects. In this study, we found that in the same model, the CB(2) agonist JWH-015 enhances neuronal nitric oxide synthase (nNOS) expression in axotomized neurons and that CB(2)-mediated neuroprotection is abrogated by pharmacological inhibition of nNOS. JWH-015 prevented the axotomy-induced upregulation of inducible NOS (iNOS) in astrocytes but had no effect on endothelial NOS (eNOS). In addition, we observed that JWH-015 significantly reduces hemicerebellectomy-induced neuroinflammatory responses and oxidative/nitrative stress. With regard to the signaling pathways of CB(2)/nNOS-mediated neuroprotection, we noted nNOS-dependent modulation of the expression of anti-oxidative (Hsp70) and anti-apoptotic (Bcl-2) proteins. These findings shed light on the interactions between the endocannabinoid and nitrergic systems after focal brain injury, implicating distinct functions of nNOS activation and iNOS inhibition in CB(2) signaling, which protect neurons from axotomy-induced cell death.

Citing Articles

Exploring β-caryophyllene: a non-psychotropic cannabinoid's potential in mitigating cognitive impairment induced by sleep deprivation.

Lim C, Ogawa S, Kumari Y Arch Pharm Res. 2024; 48(1):1-42.

PMID: 39653971 DOI: 10.1007/s12272-024-01523-z.

Emerging roles of cannabinoid receptor CB2 receptor in the central nervous system: therapeutic target for CNS disorders.

Bala K, Porel P, Aran K Psychopharmacology (Berl). 2024; 241(10):1939-1954.

PMID: 39264450 DOI: 10.1007/s00213-024-06683-w.

Effects of Long-Term Oral Administration of -Palmitoylethanolamine in Subjects with Mild Cognitive Impairment: Study Protocol.

Bossa M, Argento O, Piacentini C, Manocchio N, Scipioni L, Oddi S Brain Sci. 2023; 13(8).

PMID: 37626494 PMC: 10452679. DOI: 10.3390/brainsci13081138.

Cannabinoid CB2 Receptors in Neurodegenerative Proteinopathies: New Insights and Therapeutic Potential.

Vuic B, Milos T, Tudor L, Konjevod M, Nikolac Perkovic M, Jazvinscak Jembrek M Biomedicines. 2022; 10(12).

PMID: 36551756 PMC: 9775106. DOI: 10.3390/biomedicines10123000.

Crosstalk Between Nitric Oxide and Endocannabinoid Signaling Pathways in Normal and Pathological Placentation.

Aban C, Accialini P, Etcheverry T, Leguizamon G, Martinez N, Farina M Front Physiol. 2018; 9:1699.

PMID: 30564135 PMC: 6288445. DOI: 10.3389/fphys.2018.01699.

References

Martin L, Adams N, Pan Y, Price A, Wong M . The mitochondrial permeability transition pore regulates nitric oxide-mediated apoptosis of neurons induced by target deprivation. J Neurosci. 2011; 31(1):359-70. PMC: 3078575. DOI: 10.1523/JNEUROSCI.2225-10.2011. View

Guix F, Uribesalgo I, Coma M, Munoz F . The physiology and pathophysiology of nitric oxide in the brain. Prog Neurobiol. 2005; 76(2):126-52. DOI: 10.1016/j.pneurobio.2005.06.001. View

Jafarian-Tehrani M, Louin G, Royo N, Besson V, Bohme G, Plotkine M . 1400W, a potent selective inducible NOS inhibitor, improves histopathological outcome following traumatic brain injury in rats. Nitric Oxide. 2005; 12(2):61-9. DOI: 10.1016/j.niox.2004.12.001. View

Keilhoff G, Fansa H, Wolf G . Neuronal NOS deficiency promotes apoptotic cell death of spinal cord neurons after peripheral nerve transection. Nitric Oxide. 2004; 10(2):101-11. DOI: 10.1016/j.niox.2004.03.008. View

Levy D, Kubes P, Zochodne D . Delayed peripheral nerve degeneration, regeneration, and pain in mice lacking inducible nitric oxide synthase. J Neuropathol Exp Neurol. 2001; 60(5):411-21. DOI: 10.1093/jnen/60.5.411. View

Coleman M, Perry V . Axon pathology in neurological disease: a neglected therapeutic target. Trends Neurosci. 2002; 25(10):532-7. DOI: 10.1016/s0166-2236(02)02255-5. View

Keilhoff G, Fansa H, Wolf G . Neuronal nitric oxide synthase is the dominant nitric oxide supplier for the survival of dorsal root ganglia after peripheral nerve axotomy. J Chem Neuroanat. 2002; 24(3):181-7. DOI: 10.1016/s0891-0618(02)00055-8. View

Calabrese V, Boyd-Kimball D, Scapagnini G, Butterfield D . Nitric oxide and cellular stress response in brain aging and neurodegenerative disorders: the role of vitagenes. In Vivo. 2004; 18(3):245-67. View

Maccarrone M, Bari M, Battista N, Finazzi-Agro A . Endocannabinoid degradation, endotoxic shock and inflammation. Curr Drug Targets Inflamm Allergy. 2003; 1(1):53-63. DOI: 10.2174/1568010023344878. View

10.

Thippeswamy T, Jain R, Mumtaz N, Morris R . Inhibition of neuronal nitric oxide synthase results in neurodegenerative changes in the axotomised dorsal root ganglion neurons: evidence for a neuroprotective role of nitric oxide in vivo. Neurosci Res. 2001; 40(1):37-44. DOI: 10.1016/s0168-0102(01)00205-x. View

11.

Isaksson J, Farooque M, Olsson Y . Improved functional outcome after spinal cord injury in iNOS-deficient mice. Spinal Cord. 2004; 43(3):167-70. DOI: 10.1038/sj.sc.3101672. View

12.

Fusco F, Martorana A, Giampa C, De March Z, Farini D, DAngelo V . Immunolocalization of CB1 receptor in rat striatal neurons: a confocal microscopy study. Synapse. 2004; 53(3):159-67. DOI: 10.1002/syn.20047. View

13.

Viscomi M, Latini L, Florenzano F, Bernardi G, Molinari M . Minocycline attenuates microglial activation but fails to mitigate degeneration in inferior olive and pontine nuclei after focal cerebellar lesion. Cerebellum. 2008; 7(3):401-5. DOI: 10.1007/s12311-008-0042-z. View

14.

Koeberle P, Ball A . Nitric oxide synthase inhibition delays axonal degeneration and promotes the survival of axotomized retinal ganglion cells. Exp Neurol. 1999; 158(2):366-81. DOI: 10.1006/exnr.1999.7113. View

15.

Viscomi M, Florenzano F, Latini L, Amantea D, Bernardi G, Molinari M . Methylprednisolone treatment delays remote cell death after focal brain lesion. Neuroscience. 2008; 154(4):1267-82. DOI: 10.1016/j.neuroscience.2008.04.024. View

16.

Hillard C, Muthian S, Kearn C . Effects of CB(1) cannabinoid receptor activation on cerebellar granule cell nitric oxide synthase activity. FEBS Lett. 1999; 459(2):277-81. DOI: 10.1016/s0014-5793(99)01253-3. View

17.

Viscomi M, Florenzano F, Conversi D, Bernardi G, Molinari M . Axotomy dependent purinergic and nitrergic co-expression. Neuroscience. 2003; 123(2):393-404. DOI: 10.1016/j.neuroscience.2003.09.030. View

18.

Martin L, Price A, McClendon K, Al-Abdulla N, Subramaniam J, Wong P . Early events of target deprivation/axotomy-induced neuronal apoptosis in vivo: oxidative stress, DNA damage, p53 phosphorylation and subcellular redistribution of death proteins. J Neurochem. 2003; 85(1):234-47. DOI: 10.1046/j.1471-4159.2003.01659.x. View

19.

Stella N . Endocannabinoid signaling in microglial cells. Neuropharmacology. 2008; 56 Suppl 1:244-53. PMC: 2654419. DOI: 10.1016/j.neuropharm.2008.07.037. View

20.

Kim S, Won S, Mao X, Jin K, Greenberg D . Molecular mechanisms of cannabinoid protection from neuronal excitotoxicity. Mol Pharmacol. 2005; 69(3):691-6. DOI: 10.1124/mol.105.016428. View